Compare Mondaycom Ltd (MNDY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs GeneDx Holdings Corp — how do they compare? Mondaycom Ltd trades at $81.4 (market cap $3.53B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Mondaycom Ltd is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| MNDY | WGS | |
|---|---|---|
Market Cap | $3.53B | $2.56B |
Sector | Technology | Technology |
52-Week High | $219.15 | $167.51 |
52-Week Low | $58.81 | $34.51 |
Enterprise Value | $2.70B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNDY trades at $83.67, down 8.13% over 24 hours amid a bearish technical signal, though it holds above key support at $82. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.48 actual versus $1.11 expected, and maintains robust revenue growth, with 2025 revenue at $1.23 billion. Analyst sentiment remains positive with a consensus buy rating and a $106 price target, reflecting confidence in its enterprise software growth and AI monetization.
The outlook for MNDY is cautiously optimistic, supported by consistent earnings beats and high gross margins of 88.74%, but risks include heightened competition in SaaS and potential volatility from its elevated P/E ratio of 35.4. The stock's current dip may present a buying opportunity for growth-oriented investors, contingent on sustained execution and market conditions.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
